Please login to the form below

SAR302503

This page shows the latest SAR302503 news and features for those working in and with pharma, biotech and healthcare.

Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.

Latest news

Sanofi pulls development of blood cancer drug

The France-based pharma company said the reason to pull fedratinib – also known as SAR302503 – was due to the drug's link to an increased risk of the brain disorder
Jakavi shows long-term survival benefit in myelofibrosis

Meanwhile, Jakavi will have the market to itself for at least as a couple of years, as rival JAK inhibitors such as Sanofi's SAR302503 and Gilead Sciences' CYT387 are still
Sanofi plans to file JAK2 inhibitor after positive phase III

Sanofi has started to prepare for regulatory filings of its blood cancer treatment SAR302503 following positive results in a pivotal study. ... In the trial, patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythaemia vera
Sanofi has 65 new compounds in development, says R&D chief

Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed
Gilead expands in cancer with $510m YM BioSciences deal

Aside from Jakafi, other JAK inhibitors being developed for myelofibrosis include Sanofi's selective JAK2 inhibitor SAR302503 - phase II data for which were presented at ASH - and Cell Therapeutics Inc's

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Pharma deals during November 2013

While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Scientific Director: Great salary and bebefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Great salary and benefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Account Manager – Med Comms – London: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager – Med Comms – Kent: Salary TBC

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Account Manager or AD - Medical Communications: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Medical Writer - (London, Brighton or Copenhagen): Competitive

Project Manager, Medical Communications, London: Excellent Salary

Editor – Medical Education Agency – Bucks: Salary TBC

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Account Manager / Account Director: Great salary and bebefits

Medical Writer, e-learning/ training, London: Excellent Salary

Subscribe to our email news alerts

PMHub

Add my company

dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...